In this double-blind, randomized study of 5,300 cisgender women in South Africa and Uganda, 2,134 got the injection and the others took one of two types of daily PrEP pills. The trial began on August 2021 and, so far, not a single woman who received the injections has contracted HIV. The participants who received either of the oral PrEP options, Truvada and Descovy, had infection rates of about 2% — consistent with the infection rates of oral PrEP in other clinical trials.

These results were significant enough for the Data Monitoring Committee —- an independent group of experts appointed to assess the progress of clinical trials —- to recommend that Gilead halt its blinded trial and offer lenacapavir to all study participants. On June 20, Gilead announced these results, and now, all participants can choose to receive the injection.

A new way to prevent HIV delivers dramatic results in trial : Goats and Soda : NPR